NCT07661108PHASE1RecruitingAccepts Healthy Volunteers

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

Merck Sharp & Dohme LLC

Start Date

6/30/2026

Completion Date

10/9/2026

Summary

Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults. The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.

Eligibility Criteria

Age Range: 18 years to 55 years

Inclusion Criteria: * Be in good health * Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive Exclusion Criteria: * Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2 * Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed) * Has a history of cancer (malignancy) * Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)

Interventions

DRUG

MK-8527

DRUG

Probenecid

DRUG

Itraconazole

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Fortrea Clinical Research Unit Inc ( Site 0001)

Daytona Beach, Florida 32117

United States